Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely Zepbound Switching: How to Transition From or To Other Drugs in Class At a glance Drug / Zepbound (tirzepatide), Eli Lilly Drug class / Dual GIP and GLP-1 receptor agonist Approved indication / Chronic weight management in adults with BMI 30, or 27 with one weight-related comorbidity Dosing frequency / Once weekly subcutaneous injection Starting dose / 2.5 mg weekly, escalated every 4 weeks Maximum dose / 15 mg weekly Key trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight loss at 72 weeks on 15 mg Half-life / Approximately 5 days (supports once-weekly dosing) Common switch scenarios / Semaglutide to tirzepatide, liraglutide to tirzepatide, tirzepatide to oral semaglutide FDA approval date / November 8, 2023 (weight management indication) How Zepbound Works: Mechanism at the Receptor Level Zepbound binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
Although similar mechanisms may be involved in Se discharge from the brain, i.e., involving SELENOP and minor low molecular weight Se-metabolites, there are no relevant studies supporting this notion, to the best of the authors knowledge
These medications change appetite and metabolism, and experts warn heat can amplify certain side effects
First breath: Earths billion-year struggle for oxygen
With features like progress charts, reminders, symptom gLP-1 Journey: 6 Months of Real Data Over the last 6 months on a GLP-1, Ive tracked everything my weight, BMI, appetite changes, side effects, and even emotional ups and downs
At the bottom, it meets up with your ankle
